1.87
price up icon1.63%   0.03
after-market 시간 외 거래: 1.90 0.03 +1.60%
loading
전일 마감가:
$1.84
열려 있는:
$1.79
하루 거래량:
4.89M
Relative Volume:
2.10
시가총액:
$392.09M
수익:
$95,000
순이익/손실:
$-327.27M
주가수익비율:
-0.7633
EPS:
-2.45
순현금흐름:
$-239.25M
1주 성능:
-1.06%
1개월 성능:
-8.78%
6개월 성능:
-23.36%
1년 성능:
-32.73%
1일 변동 폭
Value
$1.78
$1.93
1주일 범위
Value
$1.78
$2.12
52주 변동 폭
Value
$1.78
$5.775

Allogene Therapeutics Inc Stock (ALLO) Company Profile

Name
명칭
Allogene Therapeutics Inc
Name
전화
(650) 457-2700
Name
주소
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Name
직원
361
Name
트위터
@AllogeneTx
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
ALLO's Discussions on Twitter

ALLO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ALLO
Allogene Therapeutics Inc
1.87 392.09M 95,000 -327.27M -239.25M -2.12
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
397.27 102.31B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
701.85 77.13B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
623.82 37.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
245.44 31.66B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
113.08 27.11B 3.30B -501.07M 1.03B -2.1146

Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-08-08 재개 Oppenheimer Outperform
2024-05-31 개시 Piper Sandler Overweight
2024-01-05 다운그레이드 Guggenheim Buy → Neutral
2024-01-05 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-08 개시 Citigroup Buy
2023-06-26 재개 Oppenheimer Outperform
2023-03-21 개시 Bernstein Mkt Perform
2023-01-24 업그레이드 JP Morgan Neutral → Overweight
2023-01-06 업그레이드 Robert W. Baird Neutral → Outperform
2022-12-12 다운그레이드 BofA Securities Buy → Underperform
2022-08-10 다운그레이드 Raymond James Outperform → Mkt Perform
2022-07-15 업그레이드 Goldman Neutral → Buy
2022-06-03 개시 Robert W. Baird Neutral
2022-02-28 재확인 B. Riley Securities Buy
2021-10-20 개시 Cowen Outperform
2021-10-08 다운그레이드 Goldman Buy → Neutral
2021-10-08 다운그레이드 Stifel Buy → Hold
2021-09-23 업그레이드 Raymond James Mkt Perform → Outperform
2021-06-21 재개 Jefferies Buy
2021-05-20 업그레이드 Truist Hold → Buy
2021-05-14 개시 B. Riley Securities Buy
2021-01-26 업그레이드 Stifel Hold → Buy
2020-12-10 재개 H.C. Wainwright Buy
2020-11-24 개시 BofA Securities Buy
2020-10-23 개시 RBC Capital Mkts Outperform
2020-06-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-29 재확인 H.C. Wainwright Buy
2020-05-19 업그레이드 ROTH Capital Neutral → Buy
2020-05-15 업그레이드 Guggenheim Neutral → Buy
2020-05-14 재확인 H.C. Wainwright Buy
2020-05-14 다운그레이드 SunTrust Buy → Hold
2020-04-13 개시 SunTrust Buy
2020-03-13 개시 H.C. Wainwright Buy
2020-03-05 개시 Stifel Hold
2020-02-24 개시 Berenberg Hold
2019-12-18 개시 JMP Securities Mkt Outperform
2019-11-04 개시 Canaccord Genuity Buy
2019-08-09 개시 BTIG Research Buy
2019-06-05 개시 ROTH Capital Neutral
2019-05-31 개시 Guggenheim Neutral
2019-05-23 개시 Stifel Hold
2019-03-29 개시 Piper Jaffray Overweight
모두보기

Allogene Therapeutics Inc 주식(ALLO)의 최신 뉴스

pulisher
Dec 18, 2024

Allogene Therapeutics (ALLO) Stock Drops Amid Biotech Sector Dec - GuruFocus.com

Dec 18, 2024
pulisher
Dec 18, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 18, 2024
pulisher
Dec 16, 2024

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

Allogene Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Dec 16, 2024
pulisher
Dec 15, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Short Interest Update - MarketBeat

Dec 15, 2024
pulisher
Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges - Investing.com Canada

Dec 13, 2024
pulisher
Dec 13, 2024

Allogene stock hits 52-week low at $1.98 amid market challenges By Investing.com - Investing.com South Africa

Dec 13, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal phase - Investing.com

Dec 12, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics (ALLO) Stock Drops Amidst Biotech Sector D - GuruFocus.com

Dec 12, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman - The Manila Times

Dec 12, 2024
pulisher
Dec 12, 2024

Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - GlobeNewswire

Dec 12, 2024
pulisher
Dec 12, 2024

Allogene Therapeutics Mourns Loss of Founding Board Member David Bonderman, Pioneer in CAR T-cell Innovation - StockTitan

Dec 12, 2024
pulisher
Dec 11, 2024

Allogene Therapeutics, Inc. Acknowledges the Passing of Founding Board Member David Bonderman - Marketscreener.com

Dec 11, 2024
pulisher
Dec 10, 2024

Insider Sell: Deborah Messemer Sells 9,136 Shares of Allogene Th - GuruFocus.com

Dec 10, 2024
pulisher
Dec 10, 2024

Allogene Therapeutics: Showing Promise Despite Some Shaky Safety (NASDAQ:ALLO) - Seeking Alpha

Dec 10, 2024
pulisher
Dec 10, 2024

Zacks Investment Management Purchases New Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 10, 2024
pulisher
Dec 09, 2024

Allogene Therapeutics (ALLO) Stock Surges Amid Positive Analyst Ratings - GuruFocus.com

Dec 09, 2024
pulisher
Dec 06, 2024

Fmr LLC Reduces Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Dec 06, 2024
pulisher
Dec 03, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decrease in Short Interest - MarketBeat

Dec 03, 2024
pulisher
Dec 02, 2024

Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? - MSN

Dec 02, 2024
pulisher
Dec 02, 2024

Allogene Therapeutics Loses 23% Year To Date: How To Play The Stock? - Barchart

Dec 02, 2024
pulisher
Nov 29, 2024

Vestal Point Capital LP Trims Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat

Nov 29, 2024
pulisher
Nov 28, 2024

Allogene’s ALLO-329 shows efficacy at killing CD19- and CD70-expressing cells - BioWorld Online

Nov 28, 2024
pulisher
Nov 25, 2024

Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why - Yahoo Finance

Nov 25, 2024
pulisher
Nov 23, 2024

Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 23, 2024
pulisher
Nov 22, 2024

ALLO (Allogene Therapeutics) Investments And Advances : $111.82 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024
pulisher
Nov 22, 2024

Is Allogene Therapeutics (NASDAQ:ALLO) In A Good Position To Invest In Growth? - Simply Wall St

Nov 22, 2024
pulisher
Nov 20, 2024

Allogene stock touches 52-week low at $2 amid market challenges - Investing.com India

Nov 20, 2024
pulisher
Nov 20, 2024

Allogene's Q3 Loss Narrower Than Expected, Sales Nil - MSN

Nov 20, 2024
pulisher
Nov 19, 2024

ALLOAllogene Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Nov 19, 2024
pulisher
Nov 19, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences - The Manila Times

Nov 19, 2024
pulisher
Nov 19, 2024

Allogene Therapeutics to Present at Three Major Healthcare Conferences | ALLO Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence - The Manila Times

Nov 18, 2024
pulisher
Nov 18, 2024

Allogene Therapeutics Presents Preclinical Data for - GlobeNewswire

Nov 18, 2024
pulisher
Nov 18, 2024

Allogene's Novel Dual CAR T ALLO-329 Shows Promise in Autoimmune Disease Study | ALLO Stock News - StockTitan

Nov 18, 2024
pulisher
Nov 18, 2024

Allogene Therapeutics, Inc Decides to Discontinue Enrollment in Its Phase 1 Cohort in the ALPHA2 Clinical Trial to Evaluate cemacabtagene ansegedleucel - Marketscreener.com

Nov 18, 2024
pulisher
Nov 18, 2024

Short Interest in Allogene Therapeutics, Inc. (NASDAQ:ALLO) Declines By 5.8% - MarketBeat

Nov 18, 2024
pulisher
Nov 15, 2024

Allogene halts enrollment in leukemia trial By Investing.com - Investing.com Australia

Nov 15, 2024
pulisher
Nov 15, 2024

Allogene’s CAR-T ALLO-316 Demonstrates Ability to Produce Responses in Renal Cell Carcinoma, but Safety Data Includes 3 On-Study Deaths - CGTLive™

Nov 15, 2024
pulisher
Nov 14, 2024

Allogene halts enrollment in leukemia trial - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Allogene Therapeutics (NASDAQ:ALLO) Shares Down 6.3% on Analyst Downgrade - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Allogene Bows to BMS in Leukemia, Ending Phase I CAR T Enrollment - BioSpace

Nov 14, 2024
pulisher
Nov 14, 2024

Piper Sandler Cuts Allogene Therapeutics (NASDAQ:ALLO) Price Target to $9.00 - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Allogene shares target cut, rating held on trial enrollment issue By Investing.com - Investing.com UK

Nov 14, 2024
pulisher
Nov 12, 2024

Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace

Nov 12, 2024
pulisher
Nov 12, 2024

Allogene Therapeutics's SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com India

Nov 12, 2024

Allogene Therapeutics Inc (ALLO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Allogene Therapeutics Inc 주식 (ALLO) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Humer Franz B
Director
Dec 05 '24
Sale
2.16
9,221
19,917
307,507
$17.87
price down icon 2.88%
$68.84
price up icon 2.65%
$39.39
price down icon 0.43%
$359.58
price down icon 0.16%
$176.50
price up icon 1.02%
$113.08
price up icon 1.56%
자본화:     |  볼륨(24시간):